文献速递神经肿瘤

奥沙利铂破坏胶质瘤细胞及相关巨噬细胞的病理特征而不依赖凋亡诱导

Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.
PubMed 文献 · J Neurooncol · 2018-08-21

研究探讨奥沙利铂对小鼠胶质瘤细胞及骨髓来源巨噬细胞的非凋亡效应。在低于诱导凋亡的浓度下,奥沙利铂降低STAT3活性与MGMT表达、增加替莫唑胺敏感性,并诱导免疫原性细胞死亡标志;内质网应激抑制可逆转上述STAT3与MGMT效应。作者认为这些发现可能对胶质母细胞瘤有治疗意义,需进一步研究。

要点

  • 亚细胞毒性浓度奥沙利铂降低胶质瘤细胞STAT3活性与MGMT水平。
  • 奥沙利铂增加胶质瘤细胞对替莫唑胺的敏感性。
  • 延长奥沙利铂处理可见免疫原性细胞死亡标志。

核心结论

  • 奥沙利铂在相对较低药物浓度下可在胶质瘤细胞和骨髓来源巨噬细胞中诱导显著的多方面生物学效应。
  • 这些发现可能对胶质母细胞瘤具有重要治疗意义,需进一步研究。

研究设计与样本

  • 研究评估奥沙利铂对小鼠KR158和GL261胶质瘤细胞及骨髓来源巨噬细胞的影响。
  • 采用细胞毒性试验、蛋白质印迹、STAT3荧光素酶报告基因试验、qRT-PCR和流式细胞术检测。
  • 使用内质网应激化学抑制剂探究该细胞损伤反应对奥沙利铂效应的贡献。

主要发现

  • 确定了奥沙利铂诱导凋亡的浓度阈值,并据此确定亚细胞毒性处理的药物剂量和治疗时长。
  • 在亚细胞毒性实验条件下,奥沙利铂降低STAT3活性、降低MGMT水平并增加替莫唑胺敏感性。
  • 延长奥沙利铂处理后有免疫原性细胞死亡证据(EIF2α磷酸化升高和钙网蛋白暴露)。
  • 抑制内质网应激可逆转奥沙利铂介导的肿瘤细胞STAT3活性抑制和MGMT表达降低。
  • 在暴露于胶质瘤条件培养基的骨髓来源巨噬细胞中,奥沙利铂降低磷酸化STAT3水平并减少精氨酸酶1表达。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出这些发现需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Emerging evidence suggests that effective treatment of glioblastoma (GBM), the most common and deadly form of adult primary brain cancer, will likely require concurrent treatment of multiple aspects of tumor pathobiology to overcome tumor heterogeneity and the complex tumor-supporting microenvironment. Recent studies in non-central nervous system (CNS) tumor cells have demonstrated that oxaliplatin (OXA) can induce multi-faceted anti-tumor effects, in particular at drug concentrations below those required to induce apoptosis. These findings motivated re-investigation of OXA for the treatment of GBM. METHODS: The effects of OXA on murine KR158 and GL261 glioma cells including cell growth, cell death, inhibition of signal transducer and activator of transcription (STAT) activity, O-6-methylguanine-DNA methyltransferase (MGMT) expression, and immunogenic cell death (ICD) initiation, were evaluated by cytotoxicity assays, Western blot analysis, STAT3-luciferase reporter assays, qRT-PCR assays, and flow cytometry. Chemical inhibitors of endoplasmic reticulum (ER) stress were used to investigate the contribution of this cell damage response to the observed OXA effects. The effect of OXA on bone marrow-derived macrophages (BMDM) exposed to glioma conditioned media (GCM) was also analyzed by Western blot analysis. RESULTS: We identified the OXA concentration threshold for induction of apoptosis and from this determined the drug dose and treatment period for sub-cytotoxic treatments of glioma cells. Under these experimental conditions, OXA reduced STAT3 activity, reduced MGMT levels and increased temozolomide sensitivity. In addition, there was evidence of immunogenic cell death (elevated EIF2α phosphorylation and calreticulin exposure) following prolonged OXA treatment. Notably, inhibition of ER stress reversed the OXA-mediated inhibition of STAT3 activity and MGMT expression in the tumor cells. In BMDMs exposed to GCM, OXA also reduced levels of phosphorylated STAT3 and decreased expression of Arginase 1, an enzyme known to contribute to pro-tumor functions in the tumor-immune environment. CONCLUSIONS: OXA can induce notable multi-faceted biological effects in glioma cells and BMDMs at relatively low drug concentrations. These findings may have significant therapeutic relevance against GBM and warrant further investigation.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Roberts NB, Alqazzaz A, Hwang JR, et al. Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction. J Neurooncol. 2018. PMID: 30132163. doi:10.1007/s11060-018-2979-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。